Sangamo Therapeutics, Inc.
SGMO
$0.15
-$0.02-12.73%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -77.60% | 88.43% | -98.82% | 5,042.13% | 1,238.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.60% | 88.43% | -98.82% | 5,042.13% | 1,238.25% |
| Cost of Revenue | 2.17% | 33.92% | 1.48% | 11.81% | -27.54% |
| Gross Profit | -28.41% | -8.08% | -227.13% | 63.22% | 44.74% |
| SG&A Expenses | -32.22% | -21.37% | -9.68% | -36.28% | -14.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.42% | 17.56% | -1.22% | -6.00% | -24.33% |
| Operating Income | -7.82% | 3.19% | -377.09% | 53.15% | 37.20% |
| Income Before Tax | -1.70% | -59.39% | -426.12% | 44.64% | 37.79% |
| Income Tax Expenses | -- | -29.51% | -282.95% | -63.51% | 21.43% |
| Earnings from Continuing Operations | -1.30% | -59.94% | -427.31% | 44.68% | 37.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.30% | -59.94% | -427.31% | 44.68% | 37.67% |
| EBIT | -7.82% | 3.19% | -377.09% | 53.15% | 37.20% |
| EBITDA | -9.15% | 2.20% | -346.02% | 54.27% | 37.50% |
| EPS Basic | 42.69% | 0.45% | -355.11% | 54.45% | 48.97% |
| Normalized Basic EPS | 42.54% | 34.76% | -285.35% | 57.31% | 44.09% |
| EPS Diluted | 42.69% | 4.40% | -387.00% | 54.45% | 48.97% |
| Normalized Diluted EPS | 42.54% | 34.76% | -290.74% | 57.31% | 44.09% |
| Average Basic Shares Outstanding | 76.88% | 60.68% | 46.04% | 25.99% | 22.14% |
| Average Diluted Shares Outstanding | 76.88% | 60.68% | 41.97% | 25.99% | 22.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |